Ieramilimab

Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy

Retrieved on: 
Wednesday, April 7, 2021

The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immuteps IMP701 antibody which is out-licensed to Novartis AG.

Key Points: 
  • The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immuteps IMP701 antibody which is out-licensed to Novartis AG.
  • In particular, the claims of the patent are directed to compositions comprising LAG525 and spartalizumab, an anti-PD-1 antibody molecule, and related methods of use of the combination in the treatment of cancer.
  • The patent is co-owned by Novartis AG and Immutep S.A.S.
  • IMP701 is a therapeutic antibody originally developed by Immutep S.A. (now Immutep S.A.S.)

Celltrion Announces Positive Interim Results From Phase I Trial of CT-P59, an Anti-COVID-19 Monoclonal Antibody Treatment Candidate

Retrieved on: 
Friday, September 11, 2020

Celltrion Group announced today interim results from the Phase I clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate.

Key Points: 
  • Celltrion Group announced today interim results from the Phase I clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate.
  • Should we receive positive results from our series of ongoing clinical trials, we intend to request emergency use authorisation for our drug.
  • Celltrion has initiated an in-human, global, Phase I clinical trial of CT-P59 in mild COVID-19 patients and plans to conduct further global Phase II and III trials in 500 patients from 12 countries including Korea.
  • The company anticipates the development of the anti-COVID-19 monoclonal antibody treatment candidate will be complete by the first half of 2021.